| The
Andhra Journal of Industrial News Chief Editor: Prof. Sreenivasarao Vepachedu, Esq (Click here to subscribe to this free e-journal) |
|
|
|
|
To join The Indian
American Chemical Society (TIACS), Please send an email to: TIACS-subscribe@yahoogroups.com |
||
|
|
|
||
| Home Management AJIN TSJ MS Vegetarian Links Disclaimer Soliciataion Contact VPC More Links Vedah |
Contents
Home of American Innovation Patent Reform Doctrine of Equivalents AstraZeneca Whacks 7600 No Need for New Drugs! Biotechnology in China BIO-Europe Green Chemistry Home of American Innovation If travel to the Washington DC area is in your plans for July and August, include a visit to the historic home of American innovation, the United States Patent and Trademark Office (USPTO). The USPTO is located in Alexandria, Virginia and is near two subway stops--King Street and Eisenhower Avenue. All this summer the USPTO is featuring an exhibit of the year's 25 best inventions as selected by the History Channel and Time Magazine. "The Modern Marvels" exhibit is free and open to the public Monday through Friday from 9 a.m. to 5 p.m. and on Saturdays from noon to 5 p.m. The exhibit is located in the atrium of the Madison Building just outside the USPTO museum. For more information on visiting the USPTO and current exhibits call 571-272-0095. http://www.uspto.gov/ Patent Reform A bill aiming to reform the United States' patent law cleared an important hurdle when it was unanimously passed by the House Judiciary Committee after a markup session. The Board of Patent Appeals and Interferences recently signaled a dramatic shift in how the PTO will deal with the obviousness question and may have raised the obviousness bar at the PTO in practice for certain predictable technologies. On July 9, 2007, OMB concluded its review of the Continuations and Claims rule changes. The final rules will be made public when they are published in the Federal Register, which is expected to be later this summer. The rules will become effective at least 60 days after publication in the Federal Register, and no earlier than October 1, 2007. http://www.uspto.gov/web/patents/notices/pclaimscont.htm Doctrine of Equivalents In a precedent-setting case over when a patent owner could claim infringement under the doctrine of equivalents, the Federal Circuit ruled that SMC Corp. did not infringe a Festo Corp. patent for rodless cylinders because SMC's device was foreseeable and prosecution history estoppel applied. http://www.patentlyo.com/patent/2007/07/further-limitat.html AstraZeneca Whacks 7600 AstraZeneca is whacking 7,600 workers off the payroll as it steps up its restructuring plans. That amounts to 11 percent of its work force. Determined to find $900 million in savings by 2010, CEO David Brennan says these cuts would hit the company's European sales and marketing operations along with R&D in a variety of countries around the globe. The cuts were announced with a second quarter earnings report that analysts regard as more evidence of a fundamentally strong company. AstraZeneca bought Cambridge Antibody Technology Group recently to help add to its portfolio of experimental therapies. AstraZeneca is also transferring some of its business to China in an attempt to keep a lid on costs. No Need for New Drugs! Older, cheaper medications for type 2 diabetes appear to be as good as newer drugs. In a study published online in the Annals of Internal Medicine, researchers looked at data from more than 200 published studies as well as unpublished information from drug companies and the Food and Drug Administration on oral diabetes drugs. Metformin, an older, cheap generic drug, did particularly well compared to other medications, it worked just as well, without causing the side effects of weight gain or blood sugar lows seen with other new drugs. Metformin also lowered bad cholesterol levels, while some newer drugs such as Avandia and Actos raised cholesterol levels. Actos and Avandia also significantly increased the risk of heart failure, the study found. Avandia has also been under scrutiny after studies published last May suggested the drug increased the risk of heart attacks. Medicines Sans Frontiers need not go after patented drugs and break patents! Poor and rich people in this world are better served with older drugs. Biotechnology in China Early in July, the government of China set out its ambitious five-year goals for the development of biotechnology. The aim of the initiative is to make China a biotech powerhouse by 2020, increasing biotech revenues to a full 4% of Chinese GDP at that time. These are aggressive plans. To get to that point, China will build on its base of independent innovation, combining it with cooperation with international biotech. Its guiding principle for growth, according to the document, is: “Led by the market, supported by the government.” BIO-Europe The leaders of the biotechnology industry will once again gather for BIO-Europe, the world’s largest stand-alone partnering conference, in Hamburg, Germany (November 12-14). This year’s edition promises to set a new standard for compelling and informative content necessary to discern opportunities in an era of significant biotech industry change. Join many of the most respected thought leaders and decision makers in the industry and examine the issues, new business approaches and policy trends most important to the emerging biotech future. A central theme to BIO-Europe 2007 will be to understand the signs, symptoms and opportunities of the much-anticipated convergence of biotech and Big Pharma. Fundamental questions, such as how can biotechnology companies help the pharmaceutical industry meet double digit growth expectations by contributing new products and processes, will be openly discussed and debated by some of the most notable names in the industry. A session destined to shake up traditional wisdom and preconceived notions of the industry is entitled, “The Changing World Order of Biotech-Pharma – How Will Emerging Realities Affect Your Business Strategy?" For Full article click here. Green Chemistry http://www.epa.gov/greenchemistry/pubs/international_activities.html Publishing cutting-edge research that reduces the environmental impact of the chemical enterprise by developing alternative sustainable technologies. http://www.rsc.org/Publishing/Journals/gc/index.asp Green Chemistry Links http://pubs.acs.org/journals/esthag/links/greenchem.html Source: The primary sources cited above, BBC News, New York Times (NYT), Washington Post (WP), Mercury News, Bayarea.com, Chicago Tribune, USA Today, Intellihealthnews, Deccan Chronicle (DC), the Hindu, Hindustan Times, Times of India, AP, Reuters, AFP, womenfitness.net, Biospace etc. Notice: The content of the articles is intended to provide general information. Specialist advice should be sought about your specific circumstances. |
(Om! Lead the world from wrong path to the right path, from ignorance to knowledge, from mortality to immortality and peace!)
One World One Family
|
|
Management |
The Andhra Journal of
Industrial News |
The Telangana Science
Journal |
Mana Sanskriti (Our
Culture) Journal |
Disclaimer | Solicitation |
Contact |
VPC |